Tumor–host interactions in the gallbladder suppress distal angiogenesis and tumor growth: Involvement of transforming growth factor β1
Open Access
- 1 October 1999
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 5 (10) , 1203-1208
- https://doi.org/10.1038/13524
Abstract
Angiogenesis inhibitors produced by a primary tumor can create a systemic anti-angiogenic environment and maintain metastatic tumor cells in a state of dormancy1,2. We show here that the gallbladder microenvironment modulates the production of transforming growth factor (TGF)-β1, a multifunctional cytokine that functions as an endogenous anti-angiogenic and anti-tumor factor in a cranial window preparation. We found that a wide variety of human gallbladder tumors express TGF-β1 irrespective of histologic type. We implanted a gel impregnated with basic fibroblast growth factor3 or Mz-ChA-2 tumor in the cranial windows of mice without tumors or mice with subcutaneous or gallbladder tumors to study angiogenesis and tumor growth at a secondary site. Angiogenesis, leukocyte–endothelial interaction in vessels and tumor growth in the cranial window were substantially inhibited in mice with gallbladder tumors. The concentration of TGF-β1 in the plasma of mice with gallbladder tumors was 300% higher than that in the plasma of mice without tumors or with subcutaneous tumors. In contrast, there was no difference in the plasma levels of other anti- and pro-angiogenic factors. Treatment with neutralizing antibody against TGF-β1 reversed both angiogenesis suppression and inhibition of leukocyte rolling induced by gallbladder tumors. TGF-β1 also inhibited Mz-ChA-2 tumor cell proliferation. Our results indicate that the production of anti-angiogenesis/proliferation factors is regulated by tumor–host interactions.Keywords
This publication has 20 references indexed in Scilit:
- A Novel, Quantitative Model for Study of Endothelial Cell Migration and Sprout Formation within Three-Dimensional Collagen MatricesMicrovascular Research, 1999
- The Expression of Vascular Endothelial Growth Factor and Transforming Growth Factor-β Associates With Angiogenesis in Epithelial Ovarian CancerInternational Journal of Gynecological Pathology, 1997
- Modulation of the Organ Microenvironment for Treatment of Cancer MetastasisJNCI Journal of the National Cancer Institute, 1995
- Transforming growth factor β and cancerCancer Treatment Reviews, 1995
- Positive correlation of plasma transforming growth factor-β1 levels with tumor vascularity in hepatocellular carcinomaCancer Letters, 1995
- Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinomaCell, 1994
- Biphasic Effect of Transforming Growth Factor-β1 on in Vitro AngiogenesisExperimental Cell Research, 1993
- Transforming growth factor beta1 in ductal carcinoma in situ and invasive carcinomas of the breastEuropean Journal Of Cancer, 1992
- Reduction of TGF‐beta activity abrogates growth promoting tumor cell‐cell interactions in vivoJournal of Cellular Physiology, 1991
- Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane.The Journal of cell biology, 1990